ATR-Chk 1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

  2015cited by this paper
• Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG).

  2015cited by this paper
• A novel compound RY10-4 downregulates P-glycoprotein expression and reverses multidrug-resistant phenotype in human breast cancer MCF-7/ADR cells.

  2014cited by this paper
• Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer

  2014cited by this paper
• A novel compound RY10-4 induces apoptosis and inhibits invasion via inhibiting STAT3 through ERK-, p38-dependent pathways in human lung adenocarcinoma A549 cells.

  2014cited by this paper
• ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF-YA

  2014cited by this paper
• Water-soluble and cleavable quercetin-amino acid conjugates as safe modulators for P-glycoprotein-based multidrug resistance.

  2014cited by this paper
• Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity.

  2014influential reference
• Targeting ATR in DNA damage response and cancer therapeutics.

  2014cited by this paper
• Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

  2014cited by this paper
• Pharmacological targeting the ATR–CHK1–WEE1 axis involves balancing cell growth stimulation and apoptosis

  2014cited by this paper
• Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma

  2014cited by this paper
• Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53

  2013cited by this paper
• Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest

  2013cited by this paper
• Molecular mechanisms of cisplatin resistance in bladder cancer

  2012cited by this paper
• Inhibition of ATR-Dependent Signaling by Protoapigenone and Its Derivative Sensitizes Cancer Cells to Interstrand Cross-link–Generating Agents In Vitro and In Vivo

  2012cited by this paper
• The DNA damage response and cancer therapy

  2012cited by this paper
• Molecular mechanisms of cisplatin resistance

  2012influential reference
• The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

  2012cited by this paper
• Selective targeting of breast cancer cells through ROS-mediated mechanisms potentiates the lethality of paclitaxel by a novel diterpene, gelomulide K.

  2011cited by this paper
• Urothelial carcinoma of the bladder: definition, treatment and future efforts

  2011cited by this paper
• A novel synthetic protoapigenone analogue, WYC02-9, induces DNA damage and apoptosis in DU145 prostate cancer cells through generation of reactive oxygen species.

  2011cited by this paper
• ATR mediates cisplatin resistance in a p53 genotype-specific manner

  2010cited by this paper
• MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

  2010cited by this paper
• Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors.

  2010cited by this paper
• Reversal of multidrug resitance by natural substances from plants.

  2010cited by this paper
• Protoapigenone, a Novel Flavonoid, Induces Apoptosis in Human Prostate Cancer Cells through Activation of p38 Mitogen-Activated Protein Kinase and c-Jun NH2-Terminal Kinase 1/2

  2008cited by this paper
• p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.

  2007cited by this paper
• First total synthesis of protoapigenone and its analogues as potent cytotoxic agents.

  2007cited by this paper
• The resurgence of platinum-based cancer chemotherapy

  2007cited by this paper
• New Cytotoxic Flavonoids from Thelypteris torresiana

  2005cited by this paper
• Pathology and staging of urothelial tumors of the kidney and ureter.

  1993cited by this paper
• Cancer statistics

  1989cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Hydrogen Sulfide Biology and Its Role in Cancer

  2022cites this paper
• Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy

  2022cites this paper
• Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis.

  2017cites this paper